文献速递炎症性肠病消化内镜

回盲部切除后内镜缓解的克罗恩病患者晚期术后复发风险:多中心10年以上研究

Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-05-20

这项在法国和比利时3个IBD中心开展的回顾性研究纳入了86例2006至2016年间接受治愈性回盲部切除术且基线内镜无复发(Rutgeerts评分<i2)的CD患者。中位随访3.5年,40.7%的患者出现晚期术后复发,中位复发时间14.2个月;复发与基线Rutgeerts评分(i0 vs i1)及是否接受药物预防均无关。

要点

  • 回盲部切除后基线内镜缓解的CD患者中约40%仍出现晚期复发。
  • 基线Rutgeerts评分i0与i1患者的晚期复发风险无显著差异。
  • 药物预防未显著降低晚期术后复发风险。

核心结论

  • 回盲部切除后初始内镜缓解的CD患者中,约40%在中位随访3.5年内出现晚期术后复发。

研究设计与样本

  • 法国和比利时3个IBD中心的回顾性研究,纳入86例2006至2016年接受治愈性回盲部切除且基线内镜无复发(Rutgeerts评分<i2)的CD患者。

主要发现

  • 基线Rutgeerts评分i0组复发20/55例,i1组复发15/31例,两组无显著差异(P=.28)。
  • 接受药物预防者复发16/40例,未接受者复发19/46例,两组无显著差异(P=.90)。
  • 71例有可用数据的患者中29例(40.8%)出现黏膜病变进展。
  • 未识别出晚期术后复发或黏膜病变进展的危险因素。

关键数值与推荐

  • 术后复发定义为临床复发、IBD相关住院、肠损伤发生、需要内镜下吻合口球囊扩张或需要再次手术的复合终点。
  • 基线内镜无复发定义为Rutgeerts评分<i2。
  • 手术至基线内镜的中位时间7个月(IQR 5.7-9.5个月),期间40例(46.5%)接受药物预防。

临床怎么用

  • 对于回盲部切除后内镜缓解的CD患者,即使基线Rutgeerts评分i0或i1,仍需在18个月后保持密切监测。

局限性

  • 回顾性研究设计,样本量86例,随访时间有限。
  • 未识别出晚期术后复发的危险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The risk of recurrence of Crohn's disease (CD) from 1 to 10 years after surgery despite initial endoscopic remission (late post-operative recurrence) is not clear. METHODS: We performed a retrospective study, at 3 inflammatory bowel disease (IBD) centers in France and Belgium, of all patients with CD (n = 86) undergoing an ileocecal resection with curative intent from 2006 through 2016 who did not have endoscopic evidence for recurrence (Rutgeerts score less than i2) at their baseline assessment. Postoperative recurrence after baseline endoscopy was defined as a composite endpoint of at least 1 of the following: clinical recurrence, IBD-related hospitalization, occurrence of bowel damage, need for endoscopic balloon dilatation of the anastomosis, and need to repeat the surgery. Risk of mucosal disease progression was studied as a secondary outcome. RESULTS: The median time between surgery and baseline endoscopy was 7 months (IQR, 5.7-9.5 months); 40 patients (46.5%) received medical prophylaxis in this period. The median follow-up time was 3.5 years (IQR, 1.6-5.3 years). Thirty-five patients (40.7%) had a late post-operative recurrence of CD, with a median time to disease recurrence after baseline endoscopy of 14.2 months (IQR, 6.3-26.1 months). Recurrence status did not differ significantly between patients with Rutgeerts scores of i0 (20/55) or i1 (15/31) at baseline (P = .28) and was independent of medical prophylaxis (16/40 with prophylactic therapy vs 19/46 without prophylactic therapy; P = .90). Mucosal disease progressed in 29 of the 71 patients (40.8%) with available data. We did not identify risk factors for late post-operative recurrence of CD or mucosal disease progression. CONCLUSIONS: Among patients with CD treated by ileocecal resection, 40% of patients had a late recurrence, despite initial endoscopic remission, after a median follow-up time of 3.5 years. Tight monitoring of these patients is recommended beyond 18 months.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Pouillon L, Remen T, Amicone C, et al. Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers. Clin Gastroenterol Hepatol. 2020. PMID: 32445951. doi:10.1016/j.cgh.2020.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。